Work

Molecular mechanisms underlying the action of histone deacetylases inhibitors (HDACIs) in ovarian cancer

Year: 2017
Type: dissertation
Abstract: Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy, despite advances in treatment. The most common histological type, high grade serous carcinoma (HGSC) is usually diagnosed at an advanced stage, and although this type of tumors frequently responds to surgery and platinum-based chemotherapy, they usually recur. Ovarian clear cell carcinoma (CCC) is an unusual histological type, which is known to be intrinsically chemoresistant and is associated with poor prognosis in advanced stages. Hence, the discovery of new therapeutic strategies urges and the fact that histone deacetylases (HDACs) expression is increased in ovarian cancer points out HDAC inhibitors (HDACIs) as an attractive approach. Our hypothesis is that HDACIs are useful drugs to treat ovarian cancer. So, the main goal was to disclose the molecular mechanisms underlying the action of HDACIs in ovarian cancer. We investigated the expression profile of HDAC, class I (HDAC1, 2, 3) and class II (HDAC4, 6 and phosphoHDAC4/5/7) in ovarian cancer. HDACs protein expression was analyzed by immunohistochemistry on tissue microarrays (TMA) from 64 patients with ovarian cancer (49 cases of HGSC and 15 cases of CCC). Our results showed that HGSC expressed HDAC1, 2, 3, 4, 6 and phosphoHDAC4/5/7 whereas CCC expressed HDAC1, 2 and 6. HDAC2, 3, 4 and pHDAC4/5/7 were associated with HGSC type. Kaplan-Meier curves showed that HDACs expression was not associated with survival. We also evaluated the association of HDACs expression profile with the cell cycle markers and we found that HDAC1 expression was statistically associated with p21 expression in HGSC. In order to understand the effects of HDACIs we used cancer cell lines (OVCAR3 and ES2) exposed to HDACIs, butyric acid and vorinostat, 5-aza-2´-deoxycytidine (DNA methylation inhibitor) and carboplatin and paclitaxel (standard chemotherapy) alone and combined. Analysis of cell death, proliferation and migration in cancer cell lines was performed. Our results showed, that both HDACIs induced cell death, mainly through apoptosis in the two cell lines. This result was further confirmed in ES2 cell line exposed to vorinostat, by the study of immunofluorescence of cleaved caspase 3 and the ratio of BAX/BCL-2 proteins, which increased after vorinostat exposure. Cell migration was decreased by vorinostat in both cancer cell lines. Our results also indicated that the association of different drugs were able to potentiate the effect of standard chemotherapy, mainly in ES2 cell line (CCC), supporting that EOC treatment can benefit from combined chemical and epigenetic therapy. Considering that CCC is a unique clinical, histopathological and molecular entity within ovarian cancer and having HNF1β as a pivotal pro-survival gene we evaluate the role of HNF1β in cell cycle arrest and apoptosis in CCC upon vorinostat exposure. Our results showed that vorinostat induced increased levels of HNF1β and at the same time cell cycle arrest and apoptosis in ES2 cells. This effect on HNF1β is associated with increased acetylation load of HNF1β. This study confirms that epigenetic modulation affects not only the conformation of chromatin and gene expression, but also it may alter the function and the turnover of proteins other than histones. Also, epigenetic modulation of signaling pathways have been reported in HGSC and CCC, including the overexpression of Notch pathway elements and we investigated the modulation of the Notch pathway by vorinostat in ovarian cancer. Using immunofluorescence and quantitative polymerase chain reaction, our results revealed that vorinostat activated the Notch pathway in CCC and HGSC cell lines, through different Notch ligands. The activation of Notch pathway by vorinostat, in CCC and HGSC cell lines, culminated in the increased expression of the same downstream transcription factors, hairy enhancer of split (Hes1) 1 and 5, and Hes-related proteins 1 and 2. Therefore, vorinostat modulates the expression of several downstream targets of the Notch pathway and independent Notch receptors and ligands that are expressed in HGSC and CCC. This upregulation of the Notch pathway may explain why vorinostat therapy fails in ovarian carcinoma treatment, as shown in certain clinical trials. We also established a cell line from ascitic fluid from a patient with HGSC, who had been previously treated with neoadjuvant chemotherapy. The cell spontaneous immortalization was obtained on 2D cell culture and expansion was performed on 2D and 3D cell cultures. Characterization studies confirmed that IPO-SOC43 cell line is of EOC origin and maintains morphological and molecular features of the primary tumor. The success of the cell line growth in a 3D systems, allows it to be used in more complex assays than those performed in 2D models. IPO-SOC43 is available for public research and we hope it can contribute to enrich the in vitro models addressing EOC heterogeneity, being useful to investigate EOC and to develop new therapeutic modalities. In conclusion, the results in vitro proved that there is benefits of combined therapy, using drugs with action of epigenetic modulation and conventional therapy. This thesis also pave the path for future studies on the role of HDACs cancer cells pathophysiology, serving as markers for the design of personalized and specific therapeutic strategies.
Language: English
Open Access status: green
OpenAlex ID: W2739130014
Cites: 109
Cited by:
Related to: 8